^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    XH001

    i
    Other names: XH001
    Associations

    News

    Trials
    Company:
    NeoCura
    Drug class:
    Immunostimulant
    Related drugs:
    Associations

    News

    Trials
    5ms
    Safety, Tolerance and Preliminary Efficacy of XH001 Injection Combined With Neoantigen Vaccine-induced Tumor-specific T-cell Injection in Advanced Gastrointestinal Cancer (clinicaltrials.gov)
    P1, N=18, Recruiting, Beijing GoBroad Hospital | Not yet recruiting --> Recruiting
    Enrollment open
    |
    XH001
    6ms
    Safety, Tolerance and Preliminary Efficacy of XH001 Injection Combined With Neoantigen Vaccine-induced Tumor-specific T-cell Injection in Advanced Gastrointestinal Cancer (clinicaltrials.gov)
    P1, N=18, Not yet recruiting, Beijing GoBroad Hospital
    New P1 trial
    |
    XH001
    9ms
    To evaluate the safety, tolerability, and preliminary efficacy of XH001 injection as adjuvant therapy in patients with high-risk recurrent solid tumors (ChiCTR2500110573)
    P1, N=48, Not yet recruiting, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences; Peking Union Medical College Hospital, Chinese Academy of Medical Sciences
    New P1 trial
    |
    XH001
    1year
    Study of XH001(Neoantigen cancer vaccine) in combination with chemtherapy for Adjuvant therapy of pancreatic cancer. (ChiCTR2500102611)
    P=N/A, N=12, Not yet recruiting, Peking Union Medical College Hospital; Peking Union Medical College Hospital
    New trial
    |
    CA 19-9 (Cancer antigen 19-9)
    |
    XH001
    over1year
    XH001 Combination With Immunocheckpoint Inhibitor and Chemotherapy for Patients With Resected Pancreatic Cancer (clinicaltrials.gov)
    P=N/A, N=24, Recruiting, Wu Wenming | Not yet recruiting --> Recruiting | N=12 --> 24
    Enrollment open • Enrollment change • Checkpoint inhibition
    |
    CA 19-9 (Cancer antigen 19-9)
    |
    Yervoy (ipilimumab) • Tyvyt (sintilimab) • capecitabine • XH001
    over2years
    XH001 Combination With Ipilimumab and Chemotherapy for Patients With Resected Pancreatic Cancer (clinicaltrials.gov)
    P=N/A, N=12, Not yet recruiting, Wu Wenming
    New trial
    |
    Yervoy (ipilimumab) • capecitabine • XH001
    3years
    A Safety and Efficacy Study of XH001 Combined With Sintilimab Injection in Advanced Solid Tumors (clinicaltrials.gov)
    P=N/A, N=9, Recruiting, jianming xu
    New trial • Metastases
    |
    Tyvyt (sintilimab) • XH001